MX2015010174A - Herramientas de diagnostico para predecir la presentacion de preeclampsia. - Google Patents

Herramientas de diagnostico para predecir la presentacion de preeclampsia.

Info

Publication number
MX2015010174A
MX2015010174A MX2015010174A MX2015010174A MX2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A
Authority
MX
Mexico
Prior art keywords
preeclampsia
diagnostic tools
predict onset
onset
predict
Prior art date
Application number
MX2015010174A
Other languages
English (en)
Inventor
Mark K Santillan
Justin L Grobe
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2015010174A publication Critical patent/MX2015010174A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11Aminopeptidases (3.4.11)
    • C12Y304/11003Cystinyl aminopeptidase (3.4.11.3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Se describen ensayos, kits, métodos, y dispositivos para diagnosticar o predecir la probabilidad de ocurrencia de preeclampsia en una paciente.
MX2015010174A 2013-02-08 2014-02-10 Herramientas de diagnostico para predecir la presentacion de preeclampsia. MX2015010174A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361762831P 2013-02-08 2013-02-08
US201361762830P 2013-02-08 2013-02-08
US201361906074P 2013-11-19 2013-11-19
PCT/US2014/015627 WO2014124392A1 (en) 2013-02-08 2014-02-10 Diagnostic tools to predict onset of preeclampsia

Publications (1)

Publication Number Publication Date
MX2015010174A true MX2015010174A (es) 2016-03-31

Family

ID=51300184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010174A MX2015010174A (es) 2013-02-08 2014-02-10 Herramientas de diagnostico para predecir la presentacion de preeclampsia.

Country Status (8)

Country Link
US (3) US20150377876A1 (es)
EP (1) EP2954324B1 (es)
JP (1) JP2016507753A (es)
KR (1) KR20150119009A (es)
CN (1) CN105308456A (es)
CA (1) CA2900366A1 (es)
MX (1) MX2015010174A (es)
WO (2) WO2014124396A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107636466B (zh) * 2015-02-18 2020-07-21 阿斯顿大学 先兆子痫的诊断性测定和治疗
PT3322985T (pt) 2015-07-15 2022-01-13 Gestvision Inc Dispositivo para detetar proteínas mal dobradas e seus métodos de uso
WO2017062270A1 (en) * 2015-10-05 2017-04-13 The Feinstein Institute For Medical Research Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies
CA2929810A1 (en) * 2016-04-29 2017-10-29 University Of Iowa Research Foundation Improved early prediction of preeclampsia
CN109891239B (zh) * 2016-10-24 2022-04-05 苏州爱尔迪思生物科技有限公司 用于提供子痫前期评估和预测早产的方法和试剂盒
US20200124612A1 (en) * 2017-04-11 2020-04-23 University Of Iowa Research Foundation Detection of predictors of preeclampsia
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α1−アンチキモトリプシンを含むバイオマーカー
CN108152495A (zh) * 2017-12-27 2018-06-12 江苏华鸣生物科技有限公司 一种检测酪氨酸的胶体金试纸
US10844435B1 (en) 2020-07-17 2020-11-24 Par Pharmaceutical, Inc. Method to treat hypotension using vasopressin in certain genotypes
CN112126683A (zh) * 2020-08-31 2020-12-25 中山大学 用于迟发型子痫前期诊断的标志物
WO2023076257A1 (en) * 2021-10-25 2023-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for diagnosing leptominingeal metastasis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733787A (en) 1996-06-17 1998-03-31 Bayer Corporation Method for the detection of creatinine
US6210971B1 (en) 1999-01-25 2001-04-03 Bayer Corporation Assay for the detection of creatinine
US20030121067A1 (en) * 2001-09-24 2003-06-26 Brennan Thomas J. V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto
JP5630936B2 (ja) 2004-02-09 2014-11-26 ラピッド パトゲン スクリーニング インコーポレイテッドRapid Pathogen Screening Inc. ヒトの体液中のターゲットを特定することにより疾病を高速に検出する方法
MXPA06012510A (es) * 2004-04-28 2006-12-15 Pfizer Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
GB0600916D0 (en) * 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
EP2139485B1 (en) 2007-04-11 2012-10-17 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20110251094A1 (en) 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
JP5959506B2 (ja) * 2010-05-14 2016-08-02 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 妊娠合併症を治療するための体外デバイスおよび方法
BR112012032406A2 (pt) * 2010-06-18 2016-10-25 Cezanne S A S marcadores para o prognóstico e avaliação de risco de hipertensão induzida pela gravidez e pré-eclâmpsia
EP2649454B1 (en) * 2010-12-06 2018-06-20 Mycartis N.V. Biomarkers and parameters for hypertensive disorders of pregnancy

Also Published As

Publication number Publication date
US20180228806A1 (en) 2018-08-16
WO2014124396A1 (en) 2014-08-14
EP2954324A1 (en) 2015-12-16
CA2900366A1 (en) 2014-08-14
EP2954324B1 (en) 2019-07-31
US9937182B2 (en) 2018-04-10
CN105308456A (zh) 2016-02-03
WO2014124392A1 (en) 2014-08-14
JP2016507753A (ja) 2016-03-10
US20150377876A1 (en) 2015-12-31
KR20150119009A (ko) 2015-10-23
EP2954324A4 (en) 2017-01-04
US20150374698A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
HK1216160A1 (zh) 執行以試劑為基礎的自動化驗的系統、方法和裝置
MA40325A (fr) Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie.
EP2972393A4 (en) BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA
EP2972308A4 (en) BIOMARKERS AND METHOD FOR PREDICTING AN EARLY BIRTH
IN2014CN04326A (es)
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
FI3511422T3 (fi) Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
EP2694667A4 (en) METHOD, COMPOSITIONS AND KITS FOR TESTING THE MITOCHONDRY FUNCTION
EP2952896A4 (en) PROCESS FOR REDUCING INCORRECT NEGATIVES IN AN IMMUNOASSAY FOR DETERMINING SPECIMENS DERIVED FROM BIOMEMBRANES
GB2532684A (en) Wellbore operations involving computational methods that produce sag profiles
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
EP2962105A4 (en) METHODS AND REAGENTS FOR DETERMINING ISOMERIC ANALYTES
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
HK1204061A1 (en) Methods and kits for detecting and diagnosing neurotrauma
EP3036712A4 (en) Methods for predicting prognosis
MX2015015015A (es) Metodo para diagnosticar cancer.
IL240129B (en) Methods and kits for determining the risk of getting extrapyramidal symptoms (eps) as a result of treatment with antipsychotics
WO2014160237A3 (en) Methods of prognosing preeclampsia
MY156871A (en) Detection methods for oil palm shell alleles
EP2972344A4 (en) Methods and compositions for diagnosing preeclampsia
IL274477A (en) Biomarker assays for use in autism surveillance
PL2759657T3 (pl) Stanowisko badawcze dla drzwi, okien i elewacji